| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [M. A. B., C. J. W., D. D. B.] and Surgery [T. J. M.], Duke University Medical Center, Durham, North Carolina 27710, and Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510 [H. F.]
The distribution and localization of a glioma-associated antigen defined by monoclonal antibody 81C6 has been examined using human cultured cell lines and tissues. Monoclonal antibody 81C6 was selected from a hybridoma fusion of spleen cells of mice immunized with the glial fibrillary acidic protein-positive human glioma cell line U-251 MG. Results of cell surface radioimmunoassay and absorption analysis demonstrated that 81C6 defined a glioma-mesenchymal extracellular matrix (GMEM) antigen expressed by 14 of 16 gliomas, 1 of 3 neuroblastomas, 1 of 7 melanomas, 2 of 6 sarcoma cell lines, and 8 of 9 cultured fibroblast lines. GMEM was not expressed by carcinoma or by the myeloid-lymphoid cell lines examined. Within the central nervous system, GMEM was expressed in 10 of 11 glioblastomas but was undetected in 5 of 6 astrocytomas and in normal adult and fetal brain by peroxidase-antiperoxidase immunohistology. In glioblastomas, the GMEM antigen was localized to basement membranes of the distinctive glomeruloid endothelial proliferations and hyperplastic blood vessels. The GMEM antigen was also expressed in 3 of 3 glioblastoma cell lines and 6 of 8 glioblastoma biopsy xenografts in athymic nude mice. Among non-central nervous system tissues and tumors, GMEM was found by peroxidase-antiperoxidase immunohistology in normal liver sinusoids, spleen red pulp sinusoids, kidney medullary tubule interstitium, and glomerular mesangium and in association with vascular and stromal elements of several undifferentiated tumors. The GMEM antigen is distinct from previously described forms of fibronectin, laminin, collagen types I to V, hyaluronic acid, chondroitin sulfate, and heparin, as determined by absorption analysis and immunohistological localization in tissues. The expression of GMEM in glioblastoma but not normal brain, association with glioblastoma-proliferative endothelium basement membranes, and expression in glioblastoma cell lines and nude mouse xenografts suggest that GMEM may be a useful marker of gliomas in vivo and in vitro.
1 Recipient of American Cancer Society Grant IM-150A in partial support of this investigation.
2 Recipient of a Faculty Research Award from the American Cancer Society in partial support of this investigation.
3 Recipient of National Cancer Institute Grant CA-32672 in partial support of this investigation. To whom requests for reprints should be addressed.
Received 2/ 4/82. Accepted 3/ 4/83.
This article has been cited by other articles:
|
|
 |
|
  B. Sivasankaran, M. Degen, A. Ghaffari, M. E. Hegi, M.-F. Hamou, M.-C. S. Ionescu, C. Zweifel, M. Tolnay, M. Wasner, S. Mergenthaler, et al. Tenascin-C Is a Novel RBPJ{kappa}-Induced Target Gene for Notch Signaling in Gliomas Cancer Res., January 15, 2009; 69(2): 458 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Reardon, M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. A. Quinn, J. N. Rich, et al. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost Neuro-oncol, April 1, 2008; 10(2): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, T. Z. Wong, and D. D. Bigner Clinical Experience with {alpha}-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 J. Nucl. Med., January 1, 2008; 49(1): 30 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, J. A. Quinn, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results J. Nucl. Med., June 1, 2006; 47(6): 912 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, J. A. Quinn, et al. Salvage Radioimmunotherapy With Murine Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results J. Clin. Oncol., January 1, 2006; 24(1): 115 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Koljonen, T Jahkola, E Tukiainen, G Granroth, C Haglund, and T Bohling Tenascin-C in primary Merkel cell carcinoma J. Clin. Pathol., March 1, 2005; 58(3): 297 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Zalutsky Current Status of Therapy of Solid Tumors: Brain Tumor Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 151S - 156S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Daniels, H. Chen, B. J. Hicke, K. M. Swiderek, and L. Gold A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment PNAS, December 23, 2003; 100(26): 15416 - 15421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hukin, J. Siffert, H. Cohen, L. Velasquez, D. Zagzag, and J. Allen Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors Neuro-oncol, July 1, 2003; 5(3): 188 - 196. [Abstract] [PDF]
|
|
|
|
|
|
D. Zagzag, B. Shiff, G. I. Jallo, M. A. Greco, C. Blanco, H. Cohen, J. Hukin, J. C. Allen, and D. R. Friedlander Tenascin-C Promotes Microvascular Cell Migration and Phosphorylation of Focal Adhesion Kinase Cancer Res., May 1, 2002; 62(9): 2660 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, G. Akabani, R. Edward Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, I. Cokgor, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al. Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas J. Clin. Oncol., March 1, 2002; 20(5): 1389 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Zalutsky, X.-G. Zhao, K. L. Alston, and D. Bigner High-Level Production of {alpha}-Particle-Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use J. Nucl. Med., October 1, 2001; 42(10): 1508 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. McLendon, C. J. Wikstrand, M. R. Matthews, R. Al-Baradei, S. H. Bigner, and D. D. Bigner Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor J. Histochem. Cytochem., August 1, 2000; 48(8): 1103 - 1110. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Sugawara, B.T. Himes, M. Kowada, M. Murray, A. Tessler, and W. P. Battisti Putative Inhibitory Extracellular Matrix Molecules Do Not Prevent Dorsal Root Regeneration into Fetal Spinal Cord Transplants Neurorehabil Neural Repair, June 1, 1999; 13(2): 135 - 147. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Carnemolla, P. Castellani, M. Ponassi, L. Borsi, S. Urbini, G. Nicolo, A. Dorcaratto, G. Viale, G. Winter, D. Neri, et al. Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant Antibody Am. J. Pathol., May 1, 1999; 154(5): 1345 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. DiScipio, P. J. Daffern, M. A. Jagels, D. H. Broide, and P. Sriramarao A Comparison of C3a and C5a-Mediated Stable Adhesion of Rolling Eosinophils in Postcapillary Venules and Transendothelial Migration In Vitro and In Vivo J. Immunol., January 15, 1999; 162(2): 1127 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mackie and R. Tucker The tenascin-C knockout revisited J. Cell Sci., January 11, 1999; 112(22): 3847 - 3853. [Abstract] [PDF]
|
|
|
|
|
|
J. Talts, G Wirl, M Dictor, W. Muller, and R Fassler Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer J. Cell Sci., January 6, 1999; 112(12): 1855 - 1864. [Abstract] [PDF]
|
|
|
|
|
|
G. Phillips, L. Krushel, and K. Crossin Domains of tenascin involved in glioma migration J. Cell Sci., January 4, 1998; 111(8): 1095 - 1104. [Abstract] [PDF]
|
|
|
|
 |
|
 H Maseruka, R E Bonshek, and A B Tullo Tenascin-C expression in normal, inflamed, and scarred human corneas Br J Ophthalmol, August 1, 1997; 81(8): 677 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I. Deryugina and M. A. Bourdon Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin J. Cell Sci., March 1, 1996; 109(3): 643 - 652. [Abstract] [PDF]
|
|
|
|
|
|
J. Talts, A Weller, R Timpl, M Ekblom, and P Ekblom Regulation of mesenchymal extracellular matrix protein synthesis by transforming growth factor-beta and glucocorticoids in tumor stroma J. Cell Sci., January 6, 1995; 108(6): 2153 - 2162. [Abstract] [PDF]
|
|
|
|
|
|
S. Redick and J. Schwarzbauer Rapid intracellular assembly of tenascin hexabrachions suggests a novel cotranslational process J. Cell Sci., January 4, 1995; 108(4): 1761 - 1769. [Abstract] [PDF]
|
|
|
|
|
|
A. Canfield and A. Schor Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells J. Cell Sci., January 2, 1995; 108(2): 797 - 809. [Abstract] [PDF]
|
|
|
|
|
|
W. Rettig, H. Erickson, A. Albino, and P Garin-Chesa Induction of human tenascin (neuronectin) by growth factors and cytokines: cell type-specific signals and signalling pathways J. Cell Sci., January 2, 1994; 107(2): 487 - 497. [Abstract] [PDF]
|
|
|
|
|
|
P Sriramarao, M Mendler, and M. Bourdon Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins J. Cell Sci., January 8, 1993; 105(4): 1001 - 1012. [Abstract] [PDF]
|
|
|
|
 |
|
 Y Saga, T Yagi, Y Ikawa, T Sakakura, and S Aizawa Mice develop normally without tenascin. Genes & Dev., October 1, 1992; 6(10): 1821 - 1831. [Abstract] [PDF]
|
|
|
|
 |
|
 P.-L. Lukinmaa, E.J. Mackie, and I. Thesleff Immunohistochemical Localization of the Matrix Glycoproteins-Tenascin and the ED-sequence-containing Form of Cellular Fibronectin--in Human Permanent Teeth and Periodontal Ligament Journal of Dental Research, January 1, 1991; 70(1): 19 - 26. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
